LB Pharmaceuticals Inc (LBRX) Key Metrics
LBRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.19B
- Enterprise value
- $1.05B
- P/E (TTM)
- 367.4
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 4.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
LBRX key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLBRX returns How much profit the business earns on the capital it uses.
LBRX financial health Debt, liquidity and how easily interest is covered.
LBRX valuation history
LBRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LBRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LBRX price vs earnings per share
LBRX key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $563.2M | — | — | — |
| Enterprise value | $271.5M | — | — | — |
| Price / book | 1.9 | — | — | — |
| Earnings yield | −4.5% | — | — | — |
| Free cash flow yield | −6.3% | — | — | — |
| Share price at fiscal year-end | $22.26 | — | — | — |
| Per share | ||||
| Revenue per share | $0.00 | — | — | — |
| Earnings per share | −$1.00 | — | — | — |
| Operating cash flow per share | −$1.39 | — | — | — |
| Free cash flow per share | −$1.39 | — | — | — |
| Cash per share | $11.67 | — | — | — |
| Book value per share | $11.91 | — | — | — |
| Tangible book value per share | $11.91 | — | — | — |
| Capex per share | $0.00 | — | — | — |
| Debt per share | $0.14 | — | — | — |
| Shares outstanding | 25.3M | — | — | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −24.4% | — | — | — |
| Return on assets (ROA) | −14.5% | −159.4% | −18.7% | −66.8% |
| Return on tangible assets | −8.1% | −188.2% | −13.7% | −66.8% |
| Financial health | ||||
| Total debt | $3.6M | $3.7M | — | $24.1M |
| Cash & short-term investments | $295.2M | $28.0M | $43.3M | $21.4M |
| Net debt | −$291.6M | −$24.3M | −$43.3M | $2.7M |
| Debt / equity | 0.01 | — | — | — |
| Debt / assets | 0.01 | 0.11 | — | 1.12 |
| Current ratio | 41.44 | 3.56 | 17.51 | 45.82 |
| Quick ratio | 41.44 | 3.56 | 17.51 | 45.82 |
| Interest coverage | — | — | -2.4 | -1.3 |
| Working capital | $301.0M | $20.8M | $43.0M | $21.0M |
| Invested capital | $9.7M | −$118.8M | −$77.8M | −$26.1M |
| Tangible asset value | $301.3M | −$94.6M | −$34.5M | −$28.8M |
| Net current asset value | $296.8M | −$99.2M | −$34.5M | −$28.8M |
| Graham net-net per share | $11.21 | — | — | — |
| Capital allocation | ||||
| Capex / depreciation | 0.16 | 8.45 | 6.25 | 0.00 |
| Efficiency | ||||
| Days payables outstanding | 2,528.3 | — | — | — |
| Payables turnover | 0.14 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $2.2M | $1.9M | $772,500 | $156,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from LBRX's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LBRX valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 367.4. LB Pharmaceuticals earned a return on equity of −24.4% in fiscal 2025. It ended the year with $3.6 million of debt and $295.2 million in cash and short-term investments, a net cash position of $291.6 million.
See the LBRX income statement, the LBRX chart for price history, or the LBRX stock overview for the latest quote and news.
LBRX key metrics FAQ
What is LB Pharmaceuticals's P/E ratio?
LB Pharmaceuticals's trailing P/E ratio is 367.4 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.
What is LB Pharmaceuticals's return on equity?
LB Pharmaceuticals's return on equity (ROE) was −24.4% in fiscal 2025: net income of -$25.2 million on average shareholders' equity of $103.4 million.
How much debt does LB Pharmaceuticals have?
LB Pharmaceuticals had total debt of $3.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is LB Pharmaceuticals's free cash flow yield?
LB Pharmaceuticals generated -$35.3 million of free cash flow in fiscal 2025, a free cash flow yield of −6.3% on its market value at year-end ($563.2 million).
What is LB Pharmaceuticals's current ratio?
LB Pharmaceuticals's current ratio was 41.44 at the end of fiscal 2025: current assets were 41.44 times current liabilities.